Post-Market Clinical Follow-up Study of i-ED Coil and EDG v4 for Arteriovenous Malformation
Safety and Efficacy of i-ED Coil and EDG v4 for Arteriovenous Malformation - A Prospective Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects aged 18 to <80 years
- Subjects requiring endovascular treatment using coils for arteriovenous malformation
- Free and informed consent to participate in the investigation obtained from the subject or an acceptable subject representative
Exclusion Criteria:
- Coiling or stenting performed on the non-target lesion within 30 days prior to treatment of the target lesion
- Hunt and Hess score of 3 or higher or modified Rankin Score (mRS) of 4 or higher
- Subjects with contraindications to CT or MRI procedures
- Subjects with contraindications to angiography procedures
- Pregnant or breastfeeding subjects
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: i-ED Coil / Electro-detach Generator v4
Participants with arteriovenous malformations (AVMs) will undergo endovascular coil embolization using the i-ED Coil in combination with the Electro Detach Generator v4 (EDG v4).
The study will collect safety and performance data during follow-up.
|
Endovascular embolization performed using the i-ED Coil, a detachable platinum coil system, in combination with the Electro Detach Generator v4 (EDG v4).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post-procedural AVM Occlusion Assessed by Angiography or MRI
Time Frame: 12, 36, 60 months
|
Complete or partial obliteration of AVMs assessed by angiography or MRI.
|
12, 36, 60 months
|
|
Successful Coil Embolization Assessed by Angiography
Time Frame: 12, 36, 60 months
|
Reduced blood flow to target vessels following coil embolization, assessed by angiography.
|
12, 36, 60 months
|
|
The Frequency of Detachment of Coils During Treatment Procedure
Time Frame: Periprocedural
|
Frequency of successful coil detachment using the EDG v4 during the treatment procedure.
|
Periprocedural
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IED-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.